Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.
The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- BioVex Group
- Catherex, Inc.
- ChemoCentryx, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Five Prime Therapeutics, Inc.
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC